Published in J Clin Microbiol on October 01, 1986
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1991) 6.17
Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans. J Clin Microbiol (1994) 5.15
Antifungal susceptibility tests. Antimicrob Agents Chemother (1987) 4.76
In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother (1989) 4.00
Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol (1994) 2.81
Collaborative investigation of broth microdilution and semisolid agar dilution for in vitro susceptibility testing of Candida albicans. J Clin Microbiol (1992) 2.12
Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group. Antimicrob Agents Chemother (1993) 1.93
Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing. J Clin Microbiol (1988) 1.71
Efficacy of SCH39304 in murine cryptococcosis. Antimicrob Agents Chemother (1989) 1.61
pH and other effects on the antifungal activity of cilofungin (LY121019). Antimicrob Agents Chemother (1989) 1.60
Broth dilution testing of Candida albicans susceptibility to ketoconazole. Antimicrob Agents Chemother (1987) 1.57
In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method. Antimicrob Agents Chemother (1992) 1.09
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis. Antimicrob Agents Chemother (2009) 0.86
Synthesis, in vitro and in vivo antifungal activity of 5-phenylthio-2,4-bisbenzyloxypyrimidine: a novel nucleobase. Indian J Pharm Sci (2010) 0.77
Comparative antifungal activity of cilofungin (LY121019) against Candida species, including evaluation of susceptibility testing method. Can J Infect Dis (1992) 0.75
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis (1972) 7.47
Azole resistance in Candida albicans. Sabouraudia (1984) 6.23
Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Antimicrob Agents Chemother (1973) 5.84
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother (1980) 4.53
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother (1982) 3.91
Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media. Antimicrob Agents Chemother (1984) 3.74
Effects of pH on the activity of ketoconazole against Candida albicans. Antimicrob Agents Chemother (1983) 3.06
In vitro activity of 5-fluorocytosine against Candida and Torulopsis species. Antimicrob Agents Chemother (1973) 2.54
The action of miconazole of the growth of Candida albicans. Sabouraudia (1975) 2.32
Susceptibility of three groups of Staphylococcus aureus to newer antimicrobial agents. Antimicrob Agents Chemother (1977) 2.09
Factors influencing the susceptibility of Candida albicans to the polyenoic antibiotics nystatin and amphotericin B. J Gen Microbiol (1978) 1.80
Comparison of microdilution and broth dilution techniques for the susceptibility testing of yeasts to 5-fluorocytosine and amphotericin B. Antimicrob Agents Chemother (1979) 1.63
Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis (1985) 1.22
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med (1991) 12.09
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol (1988) 8.67
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol (2000) 6.33
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol (1995) 6.02
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Evidence for transfer of CMY-2 AmpC beta-lactamase plasmids between Escherichia coli and Salmonella isolates from food animals and humans. Antimicrob Agents Chemother (2001) 4.66
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol (1994) 4.27
Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother (1990) 4.14
Animal and human multidrug-resistant, cephalosporin-resistant salmonella isolates expressing a plasmid-mediated CMY-2 AmpC beta-lactamase. Antimicrob Agents Chemother (2000) 4.12
Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother (2000) 4.03
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75
Use of potato flakes agar in clinical mycology. J Clin Microbiol (1982) 3.73
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J Clin Microbiol (1994) 3.62
Antifungal susceptibility testing. Current state of technology, limitations, and standardization. Infect Dis Clin North Am (1993) 3.55
Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1994) 3.46
Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother (1998) 3.45
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol (1996) 3.42
Fungal sinusitis. N Engl J Med (1997) 3.36
Branhamella (Neisseria) catarrhalis: criteria for laboratory identification. J Clin Microbiol (1980) 3.32
Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol (2002) 3.30
Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis (1997) 3.27
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother (1993) 3.25
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis (1999) 3.11
Clinical impact of rapid antimicrobial susceptibility testing of blood culture isolates. Antimicrob Agents Chemother (1982) 3.09
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother (1998) 3.06
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol (1999) 2.82
Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol (1994) 2.81
Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagn Microbiol Infect Dis (1986) 2.77
Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73
Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol (1995) 2.66
Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol (1998) 2.65
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61
Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis (1999) 2.61
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
Mycoses caused by Candida lusitaniae. Rev Infect Dis (1988) 2.53
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol (1998) 2.48
Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology (1999) 2.47
Effects of rapid detection of bloodstream infections on length of hospitalization and hospital charges. J Clin Microbiol (2003) 2.47
Standardization of antifungal susceptibility testing. J Med Vet Mycol (1992) 2.43
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis (2001) 2.39
Evaluation of a commercial latex agglutination test for identification of Staphylococcus aureus. J Clin Microbiol (1982) 2.38
Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis (1999) 2.37
Minimizing the workup of blood culture contaminants: implementation and evaluation of a laboratory-based algorithm. J Clin Microbiol (2002) 2.29
Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol (1996) 2.28
Rapid identification of Staphylococcus aureus from blood culture bottles by a classic 2-hour tube coagulase test. J Clin Microbiol (1995) 2.28
In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother (1997) 2.27
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol (2010) 2.19
Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol (2005) 2.18
Invasive aspergillosis. Rev Infect Dis (1984) 2.18
Emerging agents of phaeohyphomycosis: pathogenic species of Bipolaris and Exserohilum. J Clin Microbiol (1986) 2.17
Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis (1999) 2.16
Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother (2000) 2.13
Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol (1995) 2.13
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother (1995) 2.12
Fluconazole-resistant Candida albicans. Clin Infect Dis (1993) 2.10
Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology (2000) 2.08
The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis (2004) 2.08
Rapid detection of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. J Clin Microbiol (2009) 2.07
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis (1993) 2.03
Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin Infect Dis (1998) 2.03
Spectrum of zygomycete species identified in clinically significant specimens in the United States. J Clin Microbiol (2009) 2.02
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis (1997) 2.00
Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis (1996) 1.99
Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J Clin Microbiol (2003) 1.98
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1994) 1.95
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1991) 1.91
The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis (2001) 1.91
Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother (1989) 1.89
Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn Microbiol Infect Dis (1999) 1.88
Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates. Diagn Microbiol Infect Dis (1994) 1.88
Direct identification of Staphylococcus aureus in blood culture fluid with a commercial latex agglutination test. J Clin Microbiol (1982) 1.87
Branhamella catarrhalis--an emerging human pathogen. Diagn Microbiol Infect Dis (1986) 1.86
Antibiotic susceptibility of beta-lactamase-producing strains of Branhamella (Neisseria) catarrhalis. Antimicrob Agents Chemother (1980) 1.86
Evaluation of a direct blood culture disk diffusion antimicrobial susceptibility test. Antimicrob Agents Chemother (1981) 1.85
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother (1993) 1.83
Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. Int J Antimicrob Agents (2000) 1.83
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother (1995) 1.77
In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother (1997) 1.76
Multicenter evaluation of the use of Haemophilus test medium for broth microdilution antimicrobial susceptibility testing of Streptococcus pneumoniae and development of quality control limits. J Clin Microbiol (1992) 1.76
Detection of bacteremia in patients receiving antimicrobial therapy: an evaluation of the antimicrobial removal device and 16B medium. J Clin Microbiol (1983) 1.75
In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. Antimicrob Agents Chemother (1999) 1.75
Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole. J Antimicrob Chemother (1995) 1.72
Fluconazole disk diffusion susceptibility testing of Candida species. J Clin Microbiol (1998) 1.72
Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol (2002) 1.72
Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol (1999) 1.71